GlaxoSmithKline

GlaxoSmithKline is one of the biggest pharmaceutical companies in the world. Established in 2000 following the merger of Glaxo Wellcome and SmithKline Beecham, the company has grown to become a force to reckon within the industry. However, the company’s history dates back to 1873 when Glaxo Wellcome came into being, as a company focused on the production of dried milk baby foods.

The company has since evolved and seen its core business expand to the creation, development manufacture, and marketing of medicines, vaccines, and other healthcare-related products. The company operates under four main segments of pharmaceuticals, vaccines, pharmaceutical R&D, and consumer healthcare.

Some of its flagship products include Advaim Avodart and Lovaza. It is also the owner of the first-ever malaria vaccine.

While the company boasts of primary listing in the London Stock Exchange, the stock is also listed in the New York Stock Exchange.

Latest GlaxoSmithKline News

FTSE 100 Index – An Insight Into The Friday Trading Session

The financial experts, analysts, investors, and traders alike have been interested in the two macro events of the U.S – China trade war and the United Kingdom’s departure from the European Union for the longest time. The global financial markets...

GSK share price: Pharmco still struggles to turn profits into cash

Hargreaves Lansdown reckons that while GlaxoSmithKline (LON:GSK) has delivered profits ahead of expectations, it is still struggling to turn them into cash, Citywire reports. The comments came after the blue-chip drugmaker posted a rise in sales and earnings earlier this...

GSK share price volatile as group posts rise in Q1 sales

Shares in GlaxoSmithKline (LON:GSK) have retreated in London this afternoon following an initial jump as the blue-chip drugmaker posted a rise in sales and earnings, having benefitted from strong demand for its vaccines and HIV treatments. The company, however, continues...

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.